LV12018A - 2-metil-tieno-benzodiazepina pagatavosanas process un ta kristaliskas formas - Google Patents

2-metil-tieno-benzodiazepina pagatavosanas process un ta kristaliskas formas

Info

Publication number
LV12018A
LV12018A LV970163A LV970163A LV12018A LV 12018 A LV12018 A LV 12018A LV 970163 A LV970163 A LV 970163A LV 970163 A LV970163 A LV 970163A LV 12018 A LV12018 A LV 12018A
Authority
LV
Latvia
Prior art keywords
thien
benzodiazepine
methyl
preparation
crystalline forms
Prior art date
Application number
LV970163A
Other languages
English (en)
Other versions
LV12018B (lv
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Lilly Co Eli
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12018(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Lilly Industries Ltd filed Critical Lilly Co Eli
Publication of LV12018A publication Critical patent/LV12018A/lv
Publication of LV12018B publication Critical patent/LV12018B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
LVP-97-163A 1995-03-24 1997-09-08 2-metil-tieno-benzodiazepīna pagatavošanas process un tā kristāliskas formas LV12018B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
LV12018A true LV12018A (lv) 1998-04-20
LV12018B LV12018B (lv) 1998-09-20

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-97-163A LV12018B (lv) 1995-03-24 1997-09-08 2-metil-tieno-benzodiazepīna pagatavošanas process un tā kristāliskas formas

Country Status (49)

Country Link
US (1) US5736541A (lv)
EP (3) EP1445259B1 (lv)
JP (1) JPH11502535A (lv)
KR (1) KR100399688B1 (lv)
CN (1) CN1065536C (lv)
AP (1) AP828A (lv)
AR (2) AR002719A1 (lv)
AT (4) AT406771B (lv)
AU (1) AU706471B2 (lv)
BG (1) BG62619B1 (lv)
BR (1) BR9607790A (lv)
CA (1) CA2214005C (lv)
CH (1) CH690579A5 (lv)
CO (1) CO4650278A1 (lv)
CZ (1) CZ292688B6 (lv)
DE (4) DE69614426T2 (lv)
DK (4) DK1445259T3 (lv)
EA (1) EA000149B1 (lv)
EE (1) EE03489B1 (lv)
EG (1) EG23659A (lv)
ES (3) ES2208220T3 (lv)
FI (1) FI973750A0 (lv)
GB (1) GB2313835B (lv)
HK (1) HK1013988A1 (lv)
HU (1) HU224989B1 (lv)
IL (1) IL117610A (lv)
IS (1) IS1896B (lv)
LT (1) LT4349B (lv)
LU (1) LU90096B1 (lv)
LV (1) LV12018B (lv)
MY (1) MY114701A (lv)
NO (1) NO314663B1 (lv)
NZ (1) NZ306110A (lv)
OA (1) OA10510A (lv)
PA (1) PA8353701A1 (lv)
PE (1) PE44897A1 (lv)
PL (1) PL183723B1 (lv)
PT (3) PT733635E (lv)
RO (1) RO118872B1 (lv)
SE (1) SE9703205D0 (lv)
SI (4) SI1445259T1 (lv)
SK (1) SK284143B6 (lv)
SV (1) SV1996000031A (lv)
TR (1) TR199701017T1 (lv)
TW (2) TW513432B (lv)
UA (1) UA44765C2 (lv)
WO (1) WO1996030375A1 (lv)
YU (1) YU49478B (lv)
ZA (2) ZA962344B (lv)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
JPH11512705A (ja) * 1995-09-29 1999-11-02 イーライ・リリー・アンド・カンパニー チック症を処置する方法
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
CN1146421C (zh) * 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
IL126063A (en) * 1996-03-25 2002-04-21 Lilly Co Eli Medicinal products containing ulanzapine for the treatment of migraine pain
CA2248873A1 (en) * 1996-03-25 1997-10-02 Daniel Edward Womer Method for treating pain
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
UA56184C2 (uk) * 1996-09-23 2003-05-15 Елі Ліллі Енд Компані Поліморфна модифікація оланзапіну дигідрату d, фармацевтична композиція та спосіб лікування психотичного стану
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
EP1155696B1 (en) * 1997-04-15 2004-03-03 Eli Lilly And Company Use of olanzapine for the manufacture of a medicament for neuroprotection
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
DK1468689T3 (da) * 1998-09-30 2007-08-13 Lilly Co Eli 2-methyl-thieno-benzodiazepine formulation
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
DK1246827T3 (da) * 1999-12-28 2005-05-23 Cipla Ltd Nye polymorfe former af olanzapin
SK2502003A3 (en) * 2000-08-31 2004-03-02 Reddys Lab Ltd Dr Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
AU2002340328A1 (en) * 2001-10-29 2003-05-12 Janet I. Cord Olanzapine dihydrate-ii a process for its preparation and use thereof
AU2002367119A1 (en) * 2001-12-24 2003-07-15 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
DE60336226D1 (de) 2002-05-31 2011-04-14 Sandoz Ag Verfahren zur herstellung von olanzapin form i
JP2006500377A (ja) * 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
EP1575962A1 (en) * 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ES2232331T1 (es) * 2003-03-12 2005-06-01 Biogal Gyogyszergyar Rt. Procedimientos para la preparacion de formas polimorficas de desloratadina.
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
AU2004291043A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
CA2551806A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries, Ltd. Methods of preparing olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
DE112005000641T5 (de) 2004-09-06 2007-09-06 Shasun Chemicals and Drugs Ltd., Chennai Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin
WO2006055603A2 (en) * 2004-11-16 2006-05-26 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
BRPI0608484E2 (pt) * 2005-03-21 2014-10-29 Reddys Lab Ltd Dr Processo de preparação da forma i cristalina de olanzapina
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
PL2608670T3 (pl) 2010-08-23 2019-05-31 Alkermes Pharma Ireland Ltd Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
CN109400708A (zh) 2012-08-21 2019-03-01 詹森药业有限公司 奥氮平半抗原的抗体及其用途
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof
US20240238308A1 (en) 2023-01-10 2024-07-18 Medincell Sa Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
DE69329887T2 (de) * 1992-05-29 2001-05-23 Eli Lilly And Co., Ltd. Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
PT733635E (pt) 2001-12-28
DE19681286T1 (de) 1998-04-02
HU224989B1 (en) 2006-05-29
DK0733635T3 (da) 2001-10-08
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
DE69630324D1 (de) 2003-11-13
SV1996000031A (es) 1998-03-27
SI1095941T1 (en) 2003-12-31
LT97148A (en) 1998-01-26
NZ306110A (en) 1998-09-24
ES2266719T3 (es) 2007-03-01
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
AP828A (en) 2000-04-28
EP1445259B1 (en) 2006-06-28
SI9620040B (sl) 2002-02-28
FI973750A (fi) 1997-09-22
SK284143B6 (sk) 2004-10-05
LT4349B (lt) 1998-05-25
KR100399688B1 (ko) 2004-02-18
SE9703205L (sv) 1997-09-05
SI0733635T1 (en) 2002-06-30
EE03489B1 (et) 2001-08-15
OA10510A (en) 2002-04-24
DE69636313T2 (de) 2007-05-31
BR9607790A (pt) 1998-07-07
EG23659A (en) 2007-03-26
CN1065536C (zh) 2001-05-09
CA2214005C (en) 2001-07-03
EP0733635A1 (en) 1996-09-25
ZA962342B (en) 1997-09-22
AU5427996A (en) 1996-10-16
CN1179160A (zh) 1998-04-15
MY114701A (en) 2002-12-31
GB2313835B (en) 1998-09-16
DE69614426T2 (de) 2002-05-23
CA2214005A1 (en) 1996-10-03
ATA902196A (de) 2000-01-15
LU90096B1 (fr) 1997-07-22
GB2313835A (en) 1997-12-10
EA199700262A1 (ru) 1998-02-26
DE69614426D1 (de) 2001-09-20
ATE331719T1 (de) 2006-07-15
AT406771B (de) 2000-08-25
CO4650278A1 (es) 1998-09-03
EE9700232A (et) 1998-04-15
SE9703205D0 (sv) 1997-09-05
BG101900A (en) 1999-03-31
TW442488B (en) 2001-06-23
CZ300097A3 (en) 1997-12-17
KR19980703188A (ko) 1998-10-15
YU49478B (sh) 2006-05-25
CH690579A5 (de) 2000-10-31
UA44765C2 (uk) 2002-03-15
EP0733635B1 (en) 2001-08-16
DE69636313D1 (de) 2006-08-10
DK108997A (da) 1997-11-12
HUP9802824A3 (en) 2000-01-28
PT1095941E (pt) 2004-02-27
SI9620040A (sl) 1998-06-30
TR199701017T1 (xx) 1998-01-21
DE69630324T2 (de) 2004-07-29
ES2208220T3 (es) 2004-06-16
SI1445259T1 (sl) 2006-10-31
IS4564A (is) 1997-09-22
US5736541A (en) 1998-04-07
SK121897A3 (en) 1998-03-04
IL117610A (en) 2001-08-26
EP1095941A1 (en) 2001-05-02
EP1445259A1 (en) 2004-08-11
HK1013988A1 (en) 1999-09-17
GB9719819D0 (en) 1997-11-19
BG62619B1 (bg) 2000-03-31
TW513432B (en) 2002-12-11
DK1445259T3 (da) 2006-10-16
PL322501A1 (en) 1998-02-02
ATE251627T1 (de) 2003-10-15
AR002719A1 (es) 1998-04-29
IS1896B (is) 2003-10-20
EA000149B1 (ru) 1998-10-29
NO314663B1 (no) 2003-04-28
IL117610A0 (en) 1996-07-23
AU706471B2 (en) 1999-06-17
JPH11502535A (ja) 1999-03-02
ZA962344B (en) 1997-09-22
DK1095941T3 (da) 2004-02-16
FI973750A0 (fi) 1997-09-22
CZ292688B6 (cs) 2003-11-12
EP1095941B1 (en) 2003-10-08
RO118872B1 (ro) 2003-12-30
YU17796A (sh) 1999-03-04
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
MX9707183A (es) 1997-11-29
LV12018B (lv) 1998-09-20
ATE204280T1 (de) 2001-09-15
PE44897A1 (es) 1997-10-22
HUP9802824A2 (hu) 1999-06-28
PL183723B1 (pl) 2002-07-31
NO974365L (no) 1997-09-22
ES2159346T3 (es) 2001-10-01

Similar Documents

Publication Publication Date Title
LV12018A (lv) 2-metil-tieno-benzodiazepina pagatavosanas process un ta kristaliskas formas
NO961006D0 (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
DK0770615T3 (da) Fremgangsmåde til fremstilling af dihalogenazolopyrimidiner
GR3031759T3 (en) Toothbrush and the process for its manufacture
FI945441A (fi) Uusi menetelmä 7beta-substituoitu-4-atsa-5alfa-androstan-3-onien valmistamiseksi
NO944871D0 (no) Fremgangsmåte for fremstilling av polydimetylsiloksaner
FI940769A (fi) Menetelmä 2-aminoatsolijohdannaisten valmistamiseksi
HUP9801844A3 (en) New crystalline form of n-(4-trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid and process for the preparation thereof
DK0768310T3 (da) Fremgangsmåde til fremstilling af imidazo-benzodiazepin-derivater
EE03351B1 (et) Meetod lerkanidipiinhüdrokloriidi valmistamiseks
NO982237L (no) FremgangsmÕte for fremstilling av fenylimidazolidinderivater
NO953598L (no) Fremgangsmåte for fremstilling av akryl-piperidin-karbinoler
NO972402D0 (no) Fremgangsmåte for fremstilling av bærere
HUP9600550A2 (en) Process for the preparation of substituted cyclohexanone derivatives
ITMI931680A1 (it) Procedimento per la preparazione di alcansolfonammidi
NO304110B1 (no) FremgangsmÕte for fremstilling av glutardialdehyd
NO940171L (no) Fremgangsmåte for kontinuerlig fremstilling av dimetoksyetanal
DK0721929T3 (da) Fremgangsmåde til fremstilling af hydroxyalkoxybenzophenoner
DK0863874T3 (da) Fremgangsmåde til fremstilling af dioxoazabicyclohexaner
FI953319A0 (fi) Dimetyylinaftaleenin valmistus
EP0741126A3 (de) Verfahren zur Herstellung von Oximmethacrylaten
NO972129D0 (no) Fremgangsmåte for fremstilling av 1-halo-3-trialkylsilanyl-benzenderivater
FI943660A0 (fi) Menetelmä 3-karbonyyliandrostadieeni-17-karboksamidien valmistamiseksi
NO964519D0 (no) Fremgangsmåte for fremstilling av chitosanalkylderivater
HUP9600316A3 (en) Process for the preparation of n-(ortho-alkyl-phenyl)-imides